logo
Beyond HumanBig PictureCatalystsConnected WorldExchangeMarketing MixNew MoneyNew SchoolPeople SciencePulse

How emerging technologies are fuelling tomorrow’s drug discoveries today at GSK

John Meakin

There is no such thing as a silver bullet when it comes to business solutions, but GSK has found AI and machine learning to help both its security outfit and its drug discovery.

John Meakin, chief information security officer at GSK, reveals the extent the British pharmaceutical has invested in emerging technologies, such as AI and machine learning, to not only secure core business functions, but transform how they discover new drugs.

This interview is part of The Business of Innovation series, brought to you by Oracle Cloud.

CHANNELS